Pain-Relief Medication

PreclinicalSmall molecule

Pain-Relief Medication is one of 28 small molecule programs targeting Rotator Cuff Tear. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rotator Cuff TearActive, not recruiting

Rotator Cuff TearPreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Rotator Cuff Tear

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

—2

Naropin

FFresenius Kabi Oncology Ltd.

Approved

—3

Celebrex

PPhiladelphia Eye Associates

Marcaine

IC-Green

CCHX Technologies Inc.

Approved

—6

Decadron

AAspen Global Incorporated

Ultram

Tylenol

Depo-Testosterone

AAzurity Pharmaceuticals

Suboxone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Active, not recruiting

Rotator Cuff Tear

NCT05780229

Clinical

Trials by Indication[1]

Rotator Cuff Tear1 trial

Effectiveness of Treatments for Massive Rotator Cuff Tears: Mixed Methodology.

Active, not recruiting·PParc de Salut Mar··NCT05780229·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pain-Relief Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pain-Relief Medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pain-Relief Medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Parc de Salut Mar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PParc de Salut Mar

Pain-Relief Medication

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Rotator Cuff Tear1 trial

References

Drug Info

Quick Facts

Related News